This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Karvouni, E. Articles by Ioannidis, J. P. A. Search for Related Content PubMed PubMed Citation Articles by Karvouni, E. Articles by Ioannidis, J. P. A.

Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions

Evangelia Karvouni, MD^*, Demosthenes G. Katritsis, MD, PhD, FACC^* and John P. A. Ioannidis, MD^,*

^* Department of Cardiology, Athens Euroclinic, Athens, Greece
Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece
Division of Clinical Care Research, Tufts–New England Medical Center, Boston, Massachusetts, USA

View larger version (68K): [in a new window]   Figure 1 Mortality at 30 days (A), six months (B), and longer follow-up (C). Risk ratios and 95% confidence intervals are shown for each study and for the random effects summary (17). P = PTCA; S = stenting.